UnitedHealth Group is investing $3 billion in AI through 2027, projecting nearly $1 billion in 2026 cost savings, even as critics question whether the efficiency gains affect claims decisions.
A RAND study found 19.2% of U.S. adolescents and young adults now use AI chatbots for mental health advice, a 40% jump from the prior year, raising fresh safety and regulatory concerns.
Stanford's new SleepFM AI model, trained on 600,000 hours of sleep data, can predict risk for over 130 diseases including dementia and heart failure from a single night's sleep study.
Nvidia has built Open-H, a 778-hour open dataset of surgical robot video from 35 organizations, along with GR00T-H and Cosmos-H models meant to train and simulate surgical robots like CMR Surgical's Versius before they ever reach a real patient.
Colorado, Maine, Rhode Island, Tennessee and Vermont passed 2026 laws restricting AI chatbots from acting as therapists, joining Illinois and Nevada in a fast-growing patchwork of state rules governing AI mental health tools.
The FDA has dropped its enforcement action against Whoop over its Blood Pressure Insights feature, closing a year-long dispute that began with a 2025 warning letter and turned on new agency guidance about wellness-category wearables.
Orbis International and Siloam Vision have deployed an AI system in Mongolia that helps non-specialist clinicians screen premature infants for retinopathy of prematurity, delivering results in seconds instead of days and catching a leading cause of preventable childhood blindness.
A Harvard Medical School and Beth Israel Deaconess study published in Science found OpenAI's o1 model outdiagnosed emergency room physicians across six experiments, a result still fueling debate over AI's role in clinical care.
Hackensack Meridian Health is the first U.S. health system to earn the Joint Commission's new Responsible Use of AI in Healthcare Certification, a governance credential that checks how hospitals oversee AI tools rather than approving any single algorithm.
Insilico Medicine has launched a Phase III trial of rentosertib, an AI-designed drug for idiopathic pulmonary fibrosis, making it one of the only AI-discovered therapeutics to reach late-stage trials as the industry still awaits its first full FDA approval.